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Abstract 
Background 
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) 
provide an effective treatment option for selected patients with colorectal peritoneal 
metastasis with encouraging survival results. Many different drug combinations and HIPEC 
regimens including bidirectional, i.e. synchronous intravenous and intraperitoneal, drug 
application have been used. However, there is still no standardization of the HIPEC regimen. 
Methods 
Between 05/2007 and 04/2010 190 patients underwent CRS and HIPEC at the University 
Hospital Regensburg. Thirty-two patients with peritoneal metastasis arising from colorectal 
or appendiceal cancer underwent complete macroscopic cytoreduction (CC-0/1) and 
bidirectional HIPEC and completed at least 3-year follow-up. Twenty patients received 
oxaliplatin-based (OX) and twelve patients received irinotecan-based HIPEC (IRI). Group-
specific perioperative morbidity and 3-year survival has been determined. 
Results 
The grade 3/4 morbidity rate according to CTCAE v4 was 35.0% in the OX group vs. 33.3% 
in the IRI group (p =1.000). There was no perioperative mortality in both groups. Median 
survival was 26.8 months (95% CI 15.7-33.1 months) in the IRI group and has not yet been 
reached in the OX group during a median follow-up of 39.4 months. Three-year survival rates 
were 65.0% in the OX group vs. 41.7% in the IRI group (p =0.295). 
Conclusions 
The morbidity and toxicity rates of bidirectional irinotecan-based and oxaliplatin-based 
HIPEC are comparable. Nevertheless, in the absence of contraindications oxaliplatin-based 
HIPEC might be preferred due to the positive trend regarding 3-year and median survival. 
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Background 
The combined treatment concept consisting of cytoreductive surgery (CRS) and hyperthermic 
intraperitoneal chemotherapy (HIPEC) performed in specialized centers has shown to be a 
safe and efficient additive therapeutic option for selected patients with colorectal peritoneal 
metastasis [1-3]. One prospective randomized controlled phase III trial and several 
prospective and retrospective reports provide evidence for improved long-term survival for 
CRS and HIPEC as an integrative part of an interdisciplinary treatment regimen [4-9]. In the 
Dutch RCT the median survival of patients who underwent CRS and HIPEC was 22 months 
vs. 12.6 months in the control group with systemic chemotherapy only. In the subgroup 
analysis of patients after complete macroscopic cytoreduction (CC-0/1) median survival 
increased to 42.9 months [8,9]. As in most other reported studies and series a mitomycin C 
(MMC)-based HIPEC regimen has been used for peritoneal perfusion. Based on the results of 
modern systemic polychemotherapy regimens such as FOLFOX or FOLFIRI for patients 
with metastatic colorectal cancer oxaliplatin and irinotecan have also been used for peritoneal 
perfusion. Data first published from the French groups suggest that oxaliplatin-based HIPEC 
after complete macroscopic cytoreduction may further improve survival of patients with 
colorectal peritoneal metastasis [10,11]. The addition of intraperitoneal irinotecan to the 
bidirectional oxaliplatin-based HIPEC regimen did not lead to improved overall or relapse-
free survival [12]. Nevertheless, as irinotecan is considered to be the second most effective 
agent for the treatment of patients with colorectal cancer [13,14], bidirectional irinotecan-
based HIPEC might be a promising alternative treatment regimen for patients with disease 
progression or intolerable adverse events under oxaliplatin-based chemotherapy as well as 
patients with good response under previous systemic chemotherapy with irinotecan. 
However, conclusive data from randomized controlled trials is still missing and numerous 
different HIPEC regimens are used for treatment of colorectal peritoneal metastasis [15]. 
Cytostatic agents, drug dosage and duration of perfusion are still a matter of debate. 
In the present study we retrospectively analyzed morbidity, mortality and 3-year survival of 
thirty-two patients with peritoneal metastasis arising from colorectal or appendiceal cancer 
who received either bidirectional oxaliplatin-based or irinotecan-based HIPEC after complete 
macroscopic cytoreduction. 
Methods 
Between May 2007 and April 2010 190 patients underwent cytoreductive surgery (CRS) and 
hyperthermic intraperitoneal chemotherapy (HIPEC) for various peritoneal surface 
malignancies at the University Hospital Regensburg. Thirty-two patients with synchronous or 
metachronous peritoneal metastasis arising from colorectal or appendiceal cancer received 
bidirectional HIPEC after complete macroscopic cytoreduction (CC-0/1). Twenty patients 
received oxaliplatin-based HIPEC and twelve patients received irinotecan-based HIPEC. All 
patients had histologically proven peritoneal carcinomatosis arising from colorectal or 
appendiceal adenocarcinoma. Patients with disseminated peritoneal adenomucinosis (DPAM) 
or peritoneal mucinous carcinomatosis of intermediate features (PMCA-I) as well as patients 
with incomplete macroscopic cytoreduction (CC-2 or CC-3) were excluded from the present 
study. 
Data has been analyzed retrospectively. The retrospective analysis from a database without 
the use of patients’ personal data was exempted from approval by the Ethics Committee at 
the Regensburg University. Nevertheless, CRS and HIPEC are recommended for selected 
patients by the German S3-guideline for the treatment of colorectal cancer [16]. Moreover, 
the bidirectional oxaliplatin-based HIPEC regimen has been approved by the ethic committee 
in the context of our prospective multicenter phase II COMBATAC trial (ClinicalTrials.gov 
Identifier: NCT01540344) [17] and is recommended as one of the standard HIPEC protocols 
for patients with colorectal peritoneal metastasis by the German Peritoneal Surface 
Malignancy Group. The individual reasons for the replacement of oxaliplatin by irinotecan in 
the IRI group are summarized in Table 1. The safety of intraperitoneal application of 
irinotecan has been proven in several published studies [12,18,19]. However, due to the lack 
of consistent data there are still no national and/or international standards for HIPEC 
regimens in patients with colorectal peritoneal metastasis [15]. 
  
Table 1 Characteristics of patients with irinotecan-based HIPEC 
Patient Previous 
syst. CTx 
Previous 
syst. OX 
Recurrent PM Rationale for irinotecan-based HIPEC 
Patient 1 yes yes yes Oxaliplatin-associated peripheral neuropathy 
Patient 2 yes yes no 2nd line irinotecan-based systemic chemothera-py after disease 
progression 
Patient 3 yes no no Systemic irinotecan-based chemotherapy with response 
Patient 4 yes yes no Systemic irinotecan-based chemotherapy with response 
Patient 5 yes no no Systemic irinotecan-based chemotherapy with response 
Patient 6 yes no no Systemic irinotecan-based chemotherapy with response 
Patient 7 yes no no Systemic irinotecan-based chemotherapy with response 
Patient 8 yes yes no Oxaliplatin-associated peripheral neuropathy 
Patient 9 yes no no Systemic irinotecan-based chemotherapy with response 
Patient 10 yes yes no Progressive disease under oxaliplatin-based systemic chemotherapy 
Patient 11 yes yes yes Progressive disease under oxaliplatin-based systemic chemotherapy 
Patient 12 yes no no Systemic irinotecan-based chemotherapy with response 
CTx = chemotherapy; PM = peritoneal metastasis. 
All patients included in the present retrospective study at least completed a 3-year follow-up 
period. The median follow-up time including events of death was 37.8 months (range 7-51). 
Morbidity and toxicity were classified using the Common Terminology Criteria for Adverse 
Events version 4.0 (CTCAE v4.02) of the U.S. National Cancer Institute. Perioperative 
mortality was defined as death within 30 days after surgery or in-hospital mortality in case of 
hospital stay longer than 30 days. 
Cytoreductive surgery 
Cytoreductive surgery consists of numerous surgical and peritonectomy procedures 
depending on the extent of peritoneal tumor dissemination that was determined by the 
intraoperative calculation of the Peritoneal Cancer Index (PCI) [20,21]. Operating procedures 
were performed as described previously [22,23]. After complete macroscopic cytoreduction 
(CC-0/1) one inflow drainage, three outflow drainages and two temperature probes were 
placed in the abdomen to allow the application of HIPEC. 
Hyperthermic intraperitoneal chemotherapy 
In all patients bidirectional HIPEC with additional intravenous application of 5-FU at a 
concentration of 400 mg/sqm body surface and folinic acid at a concentration of 20 mg/sqm 
body surface about 30 minutes prior to peritoneal chemoperfusion was performed in closed 
abdomen technique. Abdominal perfusion was started with a total volume of 3 l sodium 
chloride 0.9% over the inflow drainage using a roller pump system with heat exchanger 
(ThermaSolutions Inc., Netherlands). Cytostatic agents were added after the temperature in 
Douglas pouch reached at least 40°C and perfusion was continued for 30 minutes keeping an 
intraperitoneal temperature of 41-43°C. In the OX group the abdominal cavity was perfused 
with oxaliplatin at a concentration of 300 mg/sqm body surface and in the IRI group with 300 
mg/sqm body surface irinotecan for 30 minutes, respectively. 
Statistics 
Kaplan-Maier survival analysis was performed. P-values were calculated using T-test, Chi 
square and Log rank test as applicable. A two-sided p-value <0.05 was defined to be 
statistically significant. Statistical analysis was performed using IBM SPSS Statistics for 
Windows version 19 (SPSS Inc., IBM Corporation, USA). 
Results 
Patients’ characteristics 
The mean age of patients was 54 years (range 20-68) with 53 years (range 20-68) in the OX 
group and 54 years (range 42-66) in the IRI group. Fourteen patients were female and 
eighteen male. The distribution of American Society of Anaesthesiologists (ASA) scores was 
9.4% for ASA I, 71.9% for ASA II and 18.8% for ASA III, respectively. 
Patient and tumor characteristics including localization of the primary tumor are summarized 
in Table 2. The OX group includes a higher number of patients with peritoneal metastasis 
from appendiceal adenocarcinoma (p =0.139) and a lower number with primary colon 
carcinoma (p =0.073) compared to the IRI group. Nevertheless, the differences were not 
statistically significant. Moreover, there was a not significant higher number of lymph node 
negative primary tumors (p =0.066) and well differentiated adenocarcinomas (G1, p =0.130) 
in the OX group. In one patient in the IRI group the T and N status of the primary tumor was 
not documented. 
  
Table 2 Patient and tumor characteristics 
 Overall OX IRI p-value 
Number of patients [n] 32 20 12  
I. Patient characteristics 
Mean age (range) [y] 54 (20-68) 53 (20-68) 54 (42-66) 0.842 
Sex [n]    - male 14 (43.8%) 9 (45.0%) 5 (41.7%)  
                - female 18 (56.3%) 11 (55.0%) 7 (52.8%) 1.000 
ASA score [n]     
- ASA I 3 (9.4%) 2 (10.0%) 1 (8.3%) 1.000 
- ASA II 23 (71.9%) 14 (70.0%) 9 (75.0%) 1.000 
- ASA III 6 (18.8%) 4 (20.0%) 2 (16.7%) 1.000 
II. Localization of primary tumor 
Appendix 11 (34.4%) 9 (45.0%) 2 (16.7%) 0.139 
Colon 7 (21.9%) 2 (10.0%) 5 (41.7%) 0.073 
Sigma 10 (31.3%) 7 (35.0%) 3 (25.0%) 0.702 
Rectum 4 (12.5%) 2 (10.0%) 2 (16.7%) 0.620 
III. Initial TNM classification 
T2 1* (3.2%) 1 (5.0%) 0** 1.000 
T3 10* (32.3%) 6 (30.0%) 4** (36.4%) 1.000 
T4 20* (64.5%) 13 (65.0%) 7** (63.7%) 1.000 
N0 16* (51.6%) 13 (65.0%) 3** (27.3%) 0.066 
N1 5* (16.1%) 2 (10.0%) 3** (27.3%) 0.317 
N2 10* (32.3%) 5 (25.0%) 5** (45.5%) 0.423 
M1 22 (68.8%) 14 (70.0%) 8 (66.7%) 1.000 
G1 5 (15.6%) 5 (25.0%) 0 0.130 
G2 11 (34.4%) 7 (35.0%) 4 (33.3%) 1.000 
G3 16 (50.0%) 8 (40.0%) 8 (66.7%) 0.273 
IV. Further tumor characteristics 
Mean PCI (range) 13 (2-28) 13 (4-28) 12 (2-28) 0.630 
Synchronous PM 16 (50.0%) 10 (50.0%) 6 (50.0%) 1.000 
Metachronous PM 10 (31.3%) 6 (30.0%) 4 (33.3%) 1.000 
Recurrent disease 6 (18.8%) 4 (20.0%) 2 (16.7%) 1.000 
Liver metastasis 4 (12.5%) 1 (5.0%) 3 (25.0%) 0.271 
V. Medical history 
Previous abdominal surgery 14 (43.8%) 9 (45.0%) 5 (41.7%) 1.000 
Previous oncologic surgery 24 (75.0%) 14 (70.0%) 10 (83.3%) 0.676 
Previous CRS and HIPEC 5 (15.6%) 3 (15.0%) 2 (16.7%) 1.000 
Previous chemotherapy 28 (87.5%) 16 (80.0%) 12 (100%) 0.271 
Previous systemic oxaliplatin 17 (53.1%) 11 (55.0%) 6 (50%) 1.000 
*n =31,**n =11. 
The mean PCI was 13 (range 2-18). 50% of the patients had synchronous and 31.3% 
metachronous peritoneal metastasis. Six patients showed recurrent disease (18.8%) and four 
patients had liver metastases at the time of surgery (12.5%). Fourteen patients had previous 
abdominal surgery (43.8%) and 24 patients (75.0%) already underwent oncologic abdominal 
surgery for primary tumor or metastasis. Five patients had previous CRS and HIPEC 
(15.6%). There were no significant differences between the two groups. 
Most patients (87.5%) already received systemic chemotherapy during the course of their 
disease consisting of different chemotherapy regimens. More than half of the patients 
(53.1%) had previous oxaliplatin-based systemic chemotherapy. 
Operative and perioperative data 
Operative and perioperative data is summarized in Table 3. The mean operating time was 348 
minutes (range 149-586) with 337 minutes (range 149-586) in the OX group and 366 minutes 
(range 200-557) in the IRI group, respectively (p =0.497). The mean blood loss was 271 ml 
(range 100-600), and the mean number of anastomoses was 1.19 (range 0-3). There were no 
significant differences between the two groups. 
Table 3 Operative and perioperative data 
 Overall OX IRI p-value 
Number of patients [n] 32 20 12  
I. Operative data 
Mean operating time [min] 348 (149-586) 337 366 0.497 
Mean blood loss [ml] 271 (100-600) 257 280 0.760 
Mean no. of anastomoses 1.19 1.21 1.17 0.899 
II. Perioperative data 
Median stay on ICU [d] 1 (0-6) 1 (0-5) 1.5 (0-6) 0.332 
Median hospital stay [d] 15.5 (9-42) 15 (9-38) 15.5 (8-42) 0.863 
Morbidity °3/4 [n] 11 (34.4%) 7 (35.0%) 4 (33.3%) 1.000 
In-hospital mortality [n] 0 0 0 1.000 
30-day mortality [n] 0 0 0 1.000 
Revision surgery [n] 3 (9.4%) 1 (5.0%) 2 (16.7%) 0.540 
The detailed surgical and peritonectomy procedures are summarized in Table 4. There were 
no statistically significant differences regarding surgery between the two groups. 
Table 4 Peritonectomy and surgical procedures 
 Overall OX IRI p-value 
Number of patients [n] 32 20 12  
Greater omentectomy 24 17 7 0.204 
Upper right peritonectomy 21 14 7 0.703 
Upper left peritonectomy 7 5 2 0.683 
Parietal peritonectomy 9 6 3 1.000 
Pelvic peritonectomy 22 15 7 0.438 
Small bowel resection 19 12 7 1.000 
Colonic resection 17 11 6 1.000 
Rectal resection 20 13 7 0.999 
Cholecystectomy 9 6 3 1.000 
Liver resection 5 1 4 0.053 
Gastric resection 3 1 2 0.540 
Splenectomy 6 3 3 0.647 
Ovarectomy 2 0 2 0.133 
Hysterectomy 3 1 2 0.540 
Vesical resection 2 1 1 1.000 
Loop ileostomy 4 3 1 1.000 
Overall number of peritonectomy procedures 83 57 26 0.104 
Overall number of visceral resections 86 49 37 0.142 
The median hospital stay was 15 days (range 9-38) in the OX group and 15.5 days (range 8-
42) in the IRI group, respectively (p =0.863). The median stay on ICU was one day (range 0-
6) in both groups (p =0.332). 
Morbidity and mortality 
The overall grade 3/4 morbidity rate according to CTCAE v4.02 was 34.4% with 35.0% in 
the OX group and 33.3% in the IRI group, respectively (p =1.000). Postoperative 
complications are summarized in detail in Table 5. In the OX group two patients developed 
pleural effusion requiring intervention. Moreover, ileus, intraabdominal abscess, bowel 
perforation, lung embolism, and cardiac arrhythmia were observed. In the IRI group ileus, 
postoperative bleeding, wound infection and pneumonia occurred. There was no documented 
hematological toxicity requiring intervention in both groups. Three patients (9.4%), one 
patient in the OX group (5.0%) and two patients in the IRI group (16.7%), required revision 
surgery due to postoperative complications (p =0.540). Reasons for re-operation were 
postoperative bleeding, small bowel perforation and extensive wound infection. 
Table 5 Postoperative complications grade 3/4 
 Overall OX IRI p-value 
Number of patients [n] 32 20 12  
Pleural effusion 2 (6.3%) 2 (10.0%) 0 0.516 
Pneumonia 1 (3.1%) 0 1 (8.3%) 0.375 
Lung embolism 1 (3.1%) 1 (5.0%) 0 1.000 
Bowel perforation 1 (3.1%) 1 (5.0%) 0 1.000 
Ileus 2 (6.3%) 1 (5.0%) 1 (8.3%) 1.000 
Postoperative bleeding 1 (3.1%) 0 1 (8.3%) 0.375 
Wound infection 1 (3.1%) 0 1 (8.3%) 0.375 
Intraabdominal abscess 1 (3.1%) 1 (5.0%) 0 1.000 
Cardiac arrhythmia 1 (3.1%) 1 (5.0%) 0 1.000 
Perioperative morbidity defined as 30-day or in-hospital mortality (depending on the length 
of hospital stay) was 0% in both groups. 
Survival analysis 
The overall 2-year and 3-year survival rates were 68.8% and 56.3%, respectively (Figure 
1A). The group-specific 2-year survival rates were 70.0% in the OX group and 66.7% in the 
IRI group (p =0.846). The 3-year survival rates reached 65.0% in the OX group and 41.7% in 
the IRI group (p =0.295). This difference was not statistically significant (Figure 1B). In the 
OX group median survival has not yet been reached during follow-up. The median follow-up 
time including events of death in this group of patients was 39.4 months (range 7.2-51.1). 
The IRI group showed a median survival of 26.8 months (95% CI 15.7-33.1 months). 
Figure 1 Kaplan-Meier survival analysis. A - Overall survival. n =32. 2-year survival rate 
68.8%, 3-year survival rate 56.3%. B - group-specific overall survival. 2-year survival rates: 
70.0% (OX) and 66.7% (IRI), 3-year survival rates: 65.0% (OX) and 41.7% (IRI). p =0.295 
(n.s.). OX = oxaliplatin-based HIPEC, IRI = irinotecan-based HIPEC. 
Subgroup analysis showed a 3-year overall survival rate of 72.7% in 11 patients with 
appendiceal primary compared to 47.6% in 21 patients with peritoneal metastasis arising 
from colonic, sigmoid or rectal cancer (Figure 2, p =0.213). After three years 68.8% of 
patients with negative initial lymph node status survived (n =16) compared to 46.7% of 
patients with positive lymph nodes (n =15) at time of first diagnosis (p =0.231). There was 
also no statistically significant difference regarding 3-year survival rates depending on the 
histological grading. Overall 3-year survival rates were 60.0% for patients with well 
differentiated primary tumors (G1, n =5), 54.5% for patients with moderately differentiated 
primary tumors (G2, n =11) and 53.6% for patients with poorly differentiated primary tumors 
(G3, n =16), respectively (p =0.998). 
Figure 2 3-year survival depending on primary tumor. Overall survival of patients with 
appendiceal cancer (n =11) vs. patients with colorectal cancer (n =21) as primary tumor. 3-
year survival rates: 72.7% (AC) and 47.6% (CRC). p =0.213 (n.s.). AC = appendiceal cancer, 
CRC = colorectal cancer. 
Discussion 
The multimodality treatment concept of cytoreductive surgery (CRS) and hyperthermic 
intraperitoneal chemotherapy (HIPEC) is associated with significant rates perioperative 
morbidity. Beyond patient factors such as comorbidities the operative risk of CRS depends on 
the extent of surgery and the distinctive features of the performed surgical procedures. 
HIPEC may cause additional chemotherapy-related complications and toxicity. In the 
literature morbidity rates in specialized peritoneal carcinomatosis centers range from 23% to 
45% depending on the assessment and definition of perioperative complications [3,4,7,24-
27]. Quenet et al. reported an in increase of the morbidity rate from 34.9% to 52.4% by 
adding intraperitoneal irinotecan to an oxaliplatin-based bidirectional HIPEC regimen [12]. 
In the present study the overall grade 3/4 morbidity rate was 34.4%. Although 
pharmacokinetic studies on heated intraperitoneal oxaliplatin reported dose absorption rates 
from 40% to 68% within 30 minutes perfusion [28,29], we found no hematologic toxicity 
requiring intervention neither in the OX nor in the IRI group. This result is consistent with 
previous observations [30,31]. Nevertheless, Elias et al. reported a haematological toxicity 
rate of 11% after bidirectional HIPEC with intraperitoneal oxaliplatin plus irinotecan [18]. In 
a systematic review including numerous different HIPEC regimens the mean overall rate of 
hematologic toxicity was 5.6% [32]. The low chemotherapy-related morbidity in our series 
may be caused by the concentration of 300 mg/sqm body surface in comparison to 460 
mg/sqm body surface in the French series. In a recently published study of oxaliplatin 
pharmacokinetics during bidirectional HIPEC the oxaliplatin dose has been reduced from 460 
mg/sqm body surface to 360 mg/sqm body surface after the first 17 patients due to toxicity 
[33]. 
In the present series three patients had to be re-operated for perioperative complications 
(9.4%). In the literature revision surgery is reported for 8.2% to 14% of patients that 
underwent CRS and HIPEC [3,25,26,34]. The recently published data from the American 
College of Surgeons National Surgical Quality Improvement Program showed a re-operation 
rate of 10% [35]. There was no perioperative mortality in the present study. In a systematic 
review of 155 articles published by Chua et al. the mean mortality rate was 2.9% ranging 
from 0% to 17% [32]. In the American College of Surgeons National Surgical Quality 
Improvement Program hospitals overall morbidity rate was 2% [35]. Hospital stay and stay 
on ICU did not differ between the two groups in our series and were comparable to published 
data [3,7,9,24,30,34,35]. 
The safety and efficacy of intravenous oxaliplatin and irinotecan in combination with 5-FU 
and folinic acid has been demonstrated in numerous studies [36-43]. Both cytostatic agents 
are considered to be part of the standard treatment of advanced colorectal cancer. 
Nevertheless, systemic treatment is less efficient in patients with peritoneal metastasis [44]. 
Franko et al. compared the outcome of 2,095 patients enrolled onto two prospective 
randomized clinical trials evaluating systemic chemotherapy for patients with CRC with 
(pcCRC) and without peritoneal metastasis (non-pcCRC) and reported median survival of 
12.7 months in the pcCRC group (n =364) vs. 17.6 months in the non-pcCRC group. In this 
analysis infusional oxaliplatin-based chemotherapy was superior to irinotecan in first line 
therapy of pcCRC patients [14]. 
Based on the successful use of systemic oxaliplatin, 5-fluorouracil and folinic acid in patients 
with mCRC bidirectional HIPEC with intraperitoneal oxaliplatin and intravenous 5-
FU/folinic acid has been used within the multimodality concept of CRS and HIPEC in 
patients with peritoneal metastasis arising from CRC. Elias et al. reported promising results 
with a median survival of 62.7 months and a 5-year survival rate of 51% [11]. In a 
prospective phase II study published by Hompes et al. the 2-year overall survival rate reached 
88.7% and the median disease-free survival (DFS) was 19.8 months [45]. Consistent with this 
data the 3-year survival rate in our series was 65.0%. In contrast to the results for systemic 
treatment using the FOLFOXIRI protocol published by Falcone et al. [38] addition of 
intraperitoneal irinotecan to the bidirectional oxaliplatin-based HIPEC regimen did not lead 
to improved overall or relapse-free survival. Quenet et al. reported a median overall survival 
47 months and a 5-year survival rate of 42.4% [12]. The survival data of a phase I trial 
combining irinotecan with mitomycin C for HIPEC is not yet available [19]. 
In the present retrospective analysis the rationale for intraperitoneal irinotecan was response 
to systemic irinotecan-based chemotherapy in seven patients, disease progression under 
oxaliplatin-based systemic chemotherapy in three and oxaliplatin-associated peripheral 
polyneuropathy ≥ grade 3 in two patients. Median overall survival was 26.8 months and 3-
year survival rate 41.7% in the IRI group suggesting a negative trend compared to the OX 
group as well as most published survival data after complete macroscopic cytoreduction and 
HIPEC with other cytostatic agents or combinations [8,9,11,45]. Nevertheless, in a recently 
published retrospective analysis of 95 patients Hompes et al. reported a median overall 
survival of 37.1 months after oxaliplatin-based HIPEC and 26.5 months for the mitomycin C-
based HIPEC after complete macroscopic cytoreduction [46]. This observation is supported 
by the data published from the American Society of Peritoneal Surface Malignancies showing 
a median overall survival of 32.7 months in patients treated with complete macroscopic 
cytoreduction and MMC-based HIPEC vs. 31.4 months in patients after CC-0/1-resection and 
oxaliplatin-based HIPEC [47]. Due to the small number of patients in the present series the 
survival difference between the two groups was not statistical significant (p =0.295) and 
therefore the relevance of this observation is limited. Moreover, there were a statistically not 
significant lower number of patients with appendiceal cancer and G1 differentiation as well 
as more patients with positive lymph node status in the IRI group. In a retrospective study 
Elias et al. reported a statistically significant improved overall 5-year survival rate of 63% for 
patients with peritoneal metastasis arising from appendiceal adenocarcinoma in comparison 
to colon (29.7%) and rectal cancer (37.9%). In the multivariate analysis positive lymph node 
status was an independent negative prognostic factor (p =0.001) [48]. This observation has 
been confirmed by other published data [49,50]. Nevertheless, Jimenez et al. reported a 
median survival of 47 months and a 5-year survival rate of 41% after CRS and HIPEC in 125 
patients with histologically proven peritoneal carcinomatosis (PMCA) arising from 
appendiceal cancer [51]. This survival data is comparable to the survival rates published for 
patients with colorectal peritoneal metastasis. However, in the present series the subgroup 
analysis of tumor origin, grading and lymph node status showed no significant differences. 
Conclusions 
In conclusion, our data show that both bidirectional HIPEC regimens may be used with 
comparable low mortality and acceptable morbidity in a specialized peritoneal carcinomatosis 
center. Published data and the positive trend regarding the overall 3-year survival rate in the 
present series support oxaliplatin-based HIPEC as the first choice treatment regimen. 
Nevertheless, in our opinion irinotecan-based HIPEC should still be considered as a 
promising alternative in patients with tumor progression or intolerable toxicity under 
chemotherapy with oxaliplatin. However, comparative prospective randomized trials are 
necessary to determine the best treatment regimen regarding morbidity, mortality and 
particularly long-term oncological outcome. 
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